BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/1/2014 11:47:00 AM | Browse: 1165 | Download: 1121
 |
Received |
|
2013-09-04 16:39 |
 |
Peer-Review Started |
|
2013-09-05 08:54 |
 |
To Make the First Decision |
|
2013-10-14 14:12 |
 |
Return for Revision |
|
2013-10-14 18:11 |
 |
Revised |
|
2013-11-02 18:37 |
 |
Second Decision |
|
2014-01-06 20:11 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2014-01-06 20:24 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
2014-03-25 11:28 |
 |
Typeset the Manuscript |
|
2014-04-11 09:52 |
 |
Publish the Manuscript Online |
|
2014-04-18 11:34 |
Category |
Endocrinology & Metabolism |
Manuscript Type |
Field of Vision |
Article Title |
Antidiabetic treatment, stroke severity and outcome
|
Manuscript Source |
Invited Manuscript |
All Author List |
Dimitra Magkou and Konstantinos Tziomalos |
Funding Agency and Grant Number |
|
Corresponding Author |
Konstantinos Tziomalos, MD, PhD, First Propedeutic Department of Internal Medicine, Medical School, Aristotle University of Thessaloniki, AHEPA Hospital, 1 St. Kyriakidi, Thessaloniki 54636, Greece. ktziomalos@yahoo.com |
Key Words |
Type 2 diabetes mellitus; Stroke; Dipeptidyl peptidase-4 inhibitors; Sulfonylureas; Neuroprotection |
Core Tip |
A recent study showed reduced stroke size following pretreatment with linagliptin, a dipeptidyl peptidase-4 (DDP-4) inhibitor, compared with glimepiride, in both diabetic and non-diabetic mice. It remains to be shown whether these neuroprotective actions of DPP-4 inhibitors will also be observed in humans. |
Publish Date |
2014-04-18 11:34 |
Citation |
Magkou D, Tziomalos K. Antidiabetic treatment, stroke severity and outcome. World J Diabetes 2014; 5(2): 84-88 |
URL |
http://www.wjgnet.com/1948-9358/full/v5/i2/84.htm |
DOI |
http://dx.doi.org/10.4239/wjd.v5.i2.84 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345